Utrecht: A scarring lung disease that has long outpaced the medicines available to treat it now has a fresh candidate edging toward European pharmacy shelves. At its meeting from 18 to 21 May, the European Medicines Agency’s human medicines committee handed a positive opinion to Jascayd, the brand name for nerandomilast, recommending it for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Both conditions involve irreversible thickening of lung tissue that gradually steals a patient’s ability to breathe, and clinicians across the continent have spent years working with a thin shelf of options.
The recommendation sat inside a busier-than-usual batch. The committee backed eight new medicines in total and signed off on thirteen extensions to therapies already on the market, a workload that hints at how much late-stage research is now reaching the regulator’s desk. Among the other headline opinions was Vijoice, containing alpelisib, which the committee proposed for conditional marketing authorisation in patients with severe PIK3CA-related overgrowth spectrum disorders, a cluster of rare conditions where tissue grows abnormally and treatment choices have been scarce to the point of nonexistent.
A positive opinion is not the finish line, and patients should not expect prescriptions overnight. The committee’s advice now travels to the European Commission, which issues the legally binding authorisation that makes a medicine marketable across all member states. That step usually lands within two to three months, meaning a summer decision is plausible if no complications arise. National pricing and reimbursement talks then follow, and those can stretch the gap between approval and a patient actually filling a prescription into many additional months, with wide variation from one health system to the next.
The conditional route attached to Vijoice is worth dwelling on, because it captures a recurring tension in rare-disease policy. Conditional authorisations let a drug reach patients before the full evidence package is complete, on the understanding that the manufacturer keeps supplying data afterward. Regulators lean on the tool when an unmet need is acute and the early results look convincing, but it asks health systems to accept a degree of uncertainty in exchange for speed. For families navigating conditions with almost no alternatives, that trade is often welcome; for budget holders, it complicates the arithmetic.
The pulmonary fibrosis opinion may carry the broadest reach. Idiopathic pulmonary fibrosis alone affects a meaningful slice of older Europeans, and the progressive form spans a wider group whose fibrosis stems from other underlying diseases. A therapy that slows the decline in lung function, rather than merely easing symptoms, would mark a genuine shift in what doctors can offer. Pulmonology societies will study the prescribing conditions closely once the Commission publishes them, since eligibility criteria and monitoring requirements tend to shape how widely a drug is actually used.
For the agency, the May tally reinforces a pattern of steady output as it works through a deep pipeline of oncology, rare-disease and respiratory candidates. Each positive opinion still has to survive the Commission stage and then twenty-seven separate national conversations about cost. But for patients watching the regulatory calendar, the message from this round is that the queue of new treatments keeps moving, and that two difficult disease areas may soon have more to work with than they did a month ago.
